Metabolic signaling.
Incretin analogues and peptide signals studied in glucose regulation, appetite and energy metabolism.
8 source-linked dossiers. Categories organize research context, not approved uses or promised benefits. Evidence labels refer to the sources discussed in each record.

AOD-9604
Modified growth hormone fragment
Lipid metabolism in experimental models.

Cagrilintide
Long-acting amylin analogue
Amylin-related metabolic research and controlled weight-management trials.

Liraglutide
Saxenda
Randomized diabetes and weight-management research.

Mazdutide
IBI362
Controlled metabolic studies in Chinese adult populations.

Retatrutide
LY3437943
Multi-receptor metabolic research in defined clinical populations.

Semaglutide
GLP-1 receptor agonist
Glycemic and body-weight outcomes in randomized clinical trials.

Survodutide
BI 456906
Weight-management and metabolic liver-disease clinical research.

Tirzepatide
Dual GIP / GLP-1 receptor agonist
Metabolic outcomes in randomized phase 3 studies.
Evidence labels describe the cited sources, not a complete systematic review, a safety rating or regulatory approval. This archive does not yet cover every peptide.
Read the background
Amycretin (Zenagamtide): What the New Trials Actually Show
Amycretin, now also reported as zenagamtide, is an engineered molecule with GLP-1 and amylin receptor activity.
CagriSema vs Semaglutide: How to Read Combination Evidence
CagriSema research tests coadministered cagrilintide and semaglutide, not a new name for semaglutide alone.
Eloralintide: Selective Amylin Design and the 48-Week Trial
Eloralintide research links a molecular design question with a human weight-management question.
GLP-1 Weight Loss and Muscle Loss: What DXA Can Tell You
A headline about GLP-1 muscle loss may be describing a DXA estimate of lean tissue, the proportion of lost weight classified as lean, or a direct measure of strength.
Orforglipron: Why a GLP-1 Drug Does Not Have to Be a Peptide
Orforglipron activates the GLP-1 receptor, but it is a small molecule rather than a peptide. That distinction is useful because online discussions often use GLP-1, injectable and peptide as if they were the same classification.
Pemvidutide and MASH: Liver Endpoints Beyond Weight Loss
Pemvidutide’s IMPACT report separates two liver-biopsy questions: MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH.
Petrelintide: Reading the New Amylin Research
Petrelintide is a long-acting amylin analogue being investigated through molecular-design and human clinical studies.
Retatrutide vs Tirzepatide: Receptors, Trials and Fair Comparisons
Retatrutide and tirzepatide differ in receptor-related design and in the clinical programs available for comparison.
Semaglutide and Kidney Disease: What the FLOW Trial Found
FLOW studied adults with type 2 diabetes and chronic kidney disease. Its 24% lower hazard concerned a composite of major kidney events and kidney-related or cardiovascular death.
Semaglutide and Heart Outcomes: The SELECT Population Matters
SELECT tested a cardiovascular question in adults with established cardiovascular disease and overweight or obesity, without diabetes.
Semaglutide vs Tirzepatide: What Head-to-Head Evidence Shows
SURMOUNT-5 directly compared tirzepatide with semaglutide for weight management in adults with obesity without type 2 diabetes.
Weight Regain After Stopping Semaglutide: What STEP Studied
The often-quoted claim that people regain two-thirds of their weight loss after stopping semaglutide comes from a particular follow-up study.
Tirzepatide and MASH: What SYNERGY-NASH Can Establish
A liver-enzyme improvement, a reduction in liver fat and a change in biopsy-defined MASH describe different findings.
Tirzepatide and Sleep Apnea: What SURMOUNT-OSA Measured
Tirzepatide sleep-apnea research is strongest when the breathing measurement stays attached to the result.
GLP-1, GIP, Glucagon and Amylin Peptides Compared
GLP-1, GIP, glucagon and amylin name different signaling systems, not four interchangeable versions of one weight-loss peptide.
Tirzepatide and Hunger: Appetite, Cravings and Food Intake
Hunger, cravings and measured food intake can change together, but they are not the same outcome. Tirzepatide studies have used appetite questionnaires, a controlled meal and other experimental measures to investigate those differences.
Peptide Clinical Trial Endpoints: Read Beyond the Headline
A peptide trial can measure a hormone concentration, a symptom score, a change in weight and an adverse event in the same study.